136 related articles for article (PubMed ID: 36542963)
1. Clinical characteristics and outcomes of EZH2-mutant myelodysplastic syndrome: A large single institution analysis of 1774 patients.
Ball S; Aguirre LE; Jain AG; Ali NA; Tinsley SM; Chan O; Kuykendall AT; Sweet K; Lancet JE; Sallman DA; Hussaini MO; Padron E; Komrokji RS
Leuk Res; 2023 Jan; 124():106999. PubMed ID: 36542963
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical loss of enhancer of Zeste Homolog 2 (EZH2) protein expression correlates with EZH2 alterations and portends a worse outcome in myelodysplastic syndromes.
Sakhdari A; Class C; Montalban-Bravo G; Sasaki K; Bueso-Ramos CE; Patel KP; Routbort MJ; Loghavi S; Ok CY; Quesada A; Khoury JD; Konoplev SN; Kantarjian HP; Garcia-Manero G; Medeiros LJ; Kanagal-Shamanna R
Mod Pathol; 2022 Sep; 35(9):1212-1219. PubMed ID: 35504958
[TBL] [Abstract][Full Text] [Related]
3. Integrative study of EZH2 mutational status, copy number, protein expression and H3K27 trimethylation in AML/MDS patients.
Stomper J; Meier R; Ma T; Pfeifer D; Ihorst G; Blagitko-Dorfs N; Greve G; Zimmer D; Platzbecker U; Hagemeijer A; Schmitt-Graeff I; Lübbert M
Clin Epigenetics; 2021 Apr; 13(1):77. PubMed ID: 33845873
[TBL] [Abstract][Full Text] [Related]
4. Myelodysplastic syndrome (MDS) with isolated trisomy 8: a type of MDS frequently associated with myeloproliferative features? A report by the Groupe Francophone des Myélodysplasies.
Drevon L; Marceau A; Maarek O; Cuccuini W; Clappier E; Eclache V; Cluzeau T; Richez V; Berkaoui I; Dimicoli-Salazar S; Bidet A; Vial JP; Park S; Vieira Dos Santos C; Kaphan E; Berthon C; Stamatoullas A; Delhommeau F; Abermil N; Braun T; Sapena R; Lusina D; Renneville A; Adès L; Raynaud S; Fenaux P
Br J Haematol; 2018 Sep; 182(6):843-850. PubMed ID: 30004110
[TBL] [Abstract][Full Text] [Related]
5. Genetic landscape of recurrent ASXL1, U2AF1, SF3B1, SRSF2, and EZH2 mutations in 304 Chinese patients with myelodysplastic syndromes.
Wu L; Song L; Xu L; Chang C; Xu F; Wu D; He Q; Su J; Zhou L; Xiao C; Zhang Z; Zhao Y; Chen S; Li X
Tumour Biol; 2016 Apr; 37(4):4633-40. PubMed ID: 26508027
[TBL] [Abstract][Full Text] [Related]
6. Only SF3B1 mutation involving K700E independently predicts overall survival in myelodysplastic syndromes.
Kanagal-Shamanna R; Montalban-Bravo G; Sasaki K; Darbaniyan F; Jabbour E; Bueso-Ramos C; Wei Y; Chien K; Kadia T; Ravandi F; Borthakur G; Soltysiak KA; Routbort M; Patel K; Pierce S; Medeiros LJ; Kantarjian HM; Garcia-Manero G
Cancer; 2021 Oct; 127(19):3552-3565. PubMed ID: 34161603
[TBL] [Abstract][Full Text] [Related]
7. Effect of enhancer of zeste homolog 2 mutations on the prognosis of patients with myelodysplastic syndrome: A meta-analysis.
Huang X; Wang X
Medicine (Baltimore); 2020 Aug; 99(34):e21900. PubMed ID: 32846854
[TBL] [Abstract][Full Text] [Related]
8. Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation.
Britt A; Mohyuddin GR; McClune B; Singh A; Lin T; Ganguly S; Abhyankar S; Shune L; McGuirk J; Skikne B; Godwin A; Pessetto Z; Golem S; Divine C; Dias A
Leuk Res; 2020 Aug; 95():106402. PubMed ID: 32590108
[TBL] [Abstract][Full Text] [Related]
9. Co-mutation landscape and clinical significance of RAS pathway related gene mutations in patients with myelodysplastic syndrome.
Ren Y; Lang W; Mei C; Luo Y; Ye L; Wang L; Zhou X; Xu G; Ma L; Jin J; Tong H
Hematol Oncol; 2023 Feb; 41(1):159-166. PubMed ID: 36316121
[TBL] [Abstract][Full Text] [Related]
10. Gender-related differences in the outcomes and genomic landscape of patients with myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.
Karantanos T; Gondek LP; Varadhan R; Moliterno AR; DeZern AE; Jones RJ; Jain T
Br J Haematol; 2021 Jun; 193(6):1142-1150. PubMed ID: 34028801
[TBL] [Abstract][Full Text] [Related]
11. Co-occurrence of RUNX1 and ASXL1 mutations underlie poor response and outcome for MDS patients treated with HMAs.
Wu P; Weng J; Li M; Lu Z; Deng C; Sun Q; Xu R; Geng S; Du X
Am J Transl Res; 2019; 11(6):3651-3658. PubMed ID: 31312376
[TBL] [Abstract][Full Text] [Related]
12. Concurrent loss of Ezh2 and Tet2 cooperates in the pathogenesis of myelodysplastic disorders.
Muto T; Sashida G; Oshima M; Wendt GR; Mochizuki-Kashio M; Nagata Y; Sanada M; Miyagi S; Saraya A; Kamio A; Nagae G; Nakaseko C; Yokote K; Shimoda K; Koseki H; Suzuki Y; Sugano S; Aburatani H; Ogawa S; Iwama A
J Exp Med; 2013 Nov; 210(12):2627-39. PubMed ID: 24218139
[TBL] [Abstract][Full Text] [Related]
13. [Allo-HSCT for acute myeloid leukemia with myelodysplastic-related changes: a clinical analysis].
Zhang HX; Pang AM; Chen X; Zhang RL; Zhai WH; Ma QL; Yang DL; Wei JL; He Y; Feng SZ; Han MZ; Jiang EL
Zhonghua Xue Ye Xue Za Zhi; 2021 Oct; 42(10):814-822. PubMed ID: 34788920
[No Abstract] [Full Text] [Related]
14. Mutation status and burden can improve prognostic prediction of patients with lower-risk myelodysplastic syndromes.
Jiang L; Luo Y; Zhu S; Wang L; Ma L; Zhang H; Shen C; Yang W; Ren Y; Zhou X; Mei C; Ye L; Xu W; Yang H; Lu C; Jin J; Tong H
Cancer Sci; 2020 Feb; 111(2):580-591. PubMed ID: 31804030
[TBL] [Abstract][Full Text] [Related]
15. Molecular characterization of EZH2 mutant patients with myelodysplastic/myeloproliferative neoplasms.
Rinke J; Müller JP; Blaess MF; Chase A; Meggendorfer M; Schäfer V; Winkelmann N; Haferlach C; Cross NCP; Hochhaus A; Ernst T
Leukemia; 2017 Sep; 31(9):1936-1943. PubMed ID: 28626218
[TBL] [Abstract][Full Text] [Related]
16. Prognosis and risk factors for ASXL1 mutations in patients with newly diagnosed acute myeloid leukemia and myelodysplastic syndrome.
Yang L; Wei X; Gong Y
Cancer Med; 2023 Dec; 13(1):. PubMed ID: 38146893
[TBL] [Abstract][Full Text] [Related]
17. Down-regulation of EZH2 expression in myelodysplastic syndromes.
Cabrero M; Wei Y; Yang H; Ganan-Gomez I; Bohannan Z; Colla S; Marchesini M; Bravo GM; Takahashi K; Bueso-Ramos C; Garcia-Manero G
Leuk Res; 2016 May; 44():1-7. PubMed ID: 26970171
[TBL] [Abstract][Full Text] [Related]
18. TET2, ASXL1 and EZH2 mutations in Chinese with myelodysplastic syndromes.
Wang J; Ai X; Gale RP; Xu Z; Qin T; Fang L; Zhang H; Pan L; Hu N; Zhang Y; Xiao Z
Leuk Res; 2013 Mar; 37(3):305-11. PubMed ID: 23099237
[TBL] [Abstract][Full Text] [Related]
19. Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes.
Nikoloski G; Langemeijer SM; Kuiper RP; Knops R; Massop M; Tönnissen ER; van der Heijden A; Scheele TN; Vandenberghe P; de Witte T; van der Reijden BA; Jansen JH
Nat Genet; 2010 Aug; 42(8):665-7. PubMed ID: 20601954
[TBL] [Abstract][Full Text] [Related]
20. Hypomethylating Agent Therapy in Myelodysplastic Syndromes With Chromosome 3 Abnormalities.
Sallman DA; Barnard J; Al Ali NH; Garcia-Manero G; Sekeres MA; DeZern A; Steensma DP; Roboz G; Jabbour E; Maciejewski JP; Pierce S; Padron E; Lancet JE; Kantarjian H; List AF; Komrokji RS
Clin Lymphoma Myeloma Leuk; 2020 Sep; 20(9):e597-e605. PubMed ID: 32303488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
